JGC
PRAX icon

J. Goldman & Co’s Praxis Precision Medicines PRAX Stock Holding History

J. Goldman & Co’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.38M Buy
13,600
+5,500
+68% +$1.7M 0.13% 205
2025
Q4 		$2.39M Buy
+8,100
New +$1.51M 0.06% 295

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

J. Goldman & Co's PRAX Position: Q1 2026 in Review

J. Goldman & Co increased its Praxis Precision Medicines (PRAX) stake by 182% in Q1 2026, buying an estimated $3.13M and bringing the position to 15,664 shares worth $5.05M. The position accounts for 0.15% of the portfolio, ranked #187.

J. Goldman & Co first reported a position in PRAX in Q1 2023 and has held it in 8 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • J. Goldman & Co held 15,664 shares of Praxis Precision Medicines worth $5.05M as of Q1 2026.
  • J. Goldman & Co bought 10,114 Praxis Precision Medicines shares in Q1 2026, an estimated $3.13M.
  • Praxis Precision Medicines made up 0.15% of J. Goldman & Co's portfolio in Q1 2026, its #187 holding.
  • J. Goldman & Co first reported a position in Praxis Precision Medicines in Q1 2023 and has held it in 8 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.